________________________________________________________________________________________________________________________________

© B2Bioworld 2018 Digital Pathology and its EcosystemAI-enabled Digital Pathology:
Correlate anything with everything?

Interview and Comment:  Automated and Whole Slide Imaging for Pathology 2018

October 2018. What is new about «digital pathology»? AI-enabled software and imaging will not change per se inherited theorising or practices of clinical, academic or industry professionals. A biomarker in one tissue may signal a deadly disease, the same biomarker in another tissue of the same donor may be discounted as indicating a normal or healthy state. Of course, the promise of artificial intelligence is to overcome human information processing capabilities, put inherited concepts of pathologists to the test. But, how managing the difference between «big data» and vast, widely varying amounts of clinically relevant data? How regulatory affairs act as drivers of automation and even deep learning, while challenging companies and product developers who try to exploit users’ unawareness of technological shortcomings.

Ralf Huss, Chief Medical Officer of Definiens AG which is muscling Astra Zeneca with clinical R&D intelligence, offers experience and insights to an enquiry out of the box. He also comments on technological promises by diagnostic kit providers such as Foundation Medicine, microscopy imaging systems, and IT companies offering AI simulation software. Cognitive digitization is a technological approach requiring further elaboration.

B2Bioworld's peer-reviewed chart «Digital Pathology and its Ecosystem» visualises core work flows of clinical (anatomical and other) pathologists within hospitals, in healthcare and the wider ecology. A contribution to an ongoing debate: How does the ecosystem impact pathology? How can pathology manage system interdependence and evolution? Big data, "medicine 4.0" or technology development reduced to Patient #1 are not part of the solution, but of the challenge.

If you like to read this article, you can purchase it now

Please notice, If you order by email from an organisation - for-profit or nonprofit alike - you must buy an organisation sharing license and cannot buy an individual license. However the organisation sharing license entitles you to share the article with up to four other individuals - provided you adhere to the Terms and Conditions which you agree with when purchasing articles of B2Bioworld.

Read Now - Please select your license (Prices incl. 7% VAT)
14 pages free of advertisement

Article free of advertisement

Full Company License enquire here

Back to section

Related Editorial Articles

B2Bioworld offers you background information

Crowd Sourcing Actionable Health Diagnoses
Dekel Gelbman, CEO of the FDNA Group on mobile face or pattern recognition

Regulatory Challenges of Big Data Operations – Algorithms, Healthcare, or Autonomous Driving
Herbert Zech, Professor of Life Sciences and Intellectual Property Laws at Universität Basel on key juridical concepts of the current debate about big data and artificial intelligence applications beyond privacy laws

System Biology In Search of Good Questions
Walter Kolch on the approach taken by Systems Biology Ireland

Handling Suppliers of Mass Spectrometers Delicately
Michael P. Myers, International Centre for Genetic Engineering and Biotechnology, Trieste (IT) tells how he is avoiding to get trapped by manufacturers of mass spectrometers and their strategies to fend off competitors with proprietary data formats

Roche prepares itself for user innovation
Ursula B. Redeker, CEO of Roche Germany, CEO of Roche Germany about managing “big health data”, insourcing missing expertise, and linking up to the ecosystem

Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan Knowles, Former Member of the Roche Executive Committee and Head of Group Research Leveraging different methods and technologies – clarifying the concept of personalised medicine

Metrics for Disease, Health, and Wellness
A systems look at DNA sequencing for personalized medicine by Dr Leroy Hood, President Institute for Systems Biology, Seattle

Learning Fitted to Technologies, or Technologies for Learning
Hanne Leth Andersen, Professor of University Pedagogy at Danish Roskilde University invites readers of B2Bioworld to a light-hearted and thought-provoking tour de ronde

Steering Health Data For or By? The User as Stakeholder, Expert, Citizen, Consumer, and Patient
Thomas Szucs, Chairman of Swiss Helsana Group on putting “big data” to work in insurance and healthcare

AstraZeneca and MedImmune Trigger Public Investments into Brazil's Translational Healthcare
A public-private partnership becomes a building block of São Paulo State’s industrial diversification strategy of State

Systems Biology Applied
Rudi Balling, Director Luxembourg Centre for Systems Biomedicine on the Need of Systems Theory Thinking in Using Technologies and Pitfalls of Key Concepts

Transition of Cancer Research Translation
Christof von Kalle, Head of Germany’s National Center for Tumor Diseases on transitions in translational cancer research